A Multicentre, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis and Early Stage Acute Liver Failure
Latest Information Update: 07 Nov 2021
At a glance
- Drugs ALF 5755 (Primary)
- Indications Hepatitis; Liver failure
- Focus Therapeutic Use
- Sponsors Alfact Innovation
- 21 Nov 2013 New trial record
- 04 Nov 2013 Results published in an Alfact Innovation media release.
- 04 Nov 2013 Status changed from recruiting to completed, based on reported results in an Alfact Innovation media release.